Skip to main content
SpringerLink
Log in

Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110. https://doi.org/10.1056/NEJMoa1313984

    Article  CAS  PubMed  Google Scholar 

  2. Raisch DW, Rafi JA, Chen C, Bennett CL (2016) Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system. Expert Opin Drug Saf 15(8):1003–1011. https://doi.org/10.1080/14740338.2016.1198775

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Edelmann J, Gribben JG (2016) Obinutuzumab for the treatment of indolent lymphoma. Future Oncol 12(15):1769–1781. https://doi.org/10.2217/fon-2016-0084

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Fernandez O (2013) Best practice in the use of natalizumab in multiple sclerosis. Ther Adv Neurol Disord 6(2):69–79. https://doi.org/10.1177/1756285612470401

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia

    Vlatko Pejsa, Marko Lucijanic, Zeljko Jonjic & Zeljko Prka

  2. School of Medicine, University of Zagreb, Zagreb, Croatia

    Vlatko Pejsa

  3. Neurology Department, University Hospital Dubrava, Zagreb, Croatia

    Gorana Vukorepa

Authors
  1. Vlatko Pejsa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marko Lucijanic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zeljko Jonjic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zeljko Prka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gorana Vukorepa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vlatko Pejsa.

Ethics declarations

Conflict of interest

VP, ML, and ZP have received a speaker honorarium from Roche. Other authors declare that they have no conflict of interest.

Ethical statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Informed consent

Patient’s family provided informed consent for publishing.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pejsa, V., Lucijanic, M., Jonjic, Z. et al. Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia. Ann Hematol 98, 1509–1510 (2019). https://doi.org/10.1007/s00277-018-3552-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-018-3552-x

Search

Navigation